Clinical Trials Logo

Glioblastoma Multiforme of Brain clinical trials

View clinical trials related to Glioblastoma Multiforme of Brain.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04968366 Active, not recruiting - Clinical trials for Glioblastoma Multiforme of Brain

Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery

Start date: July 30, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, single-arm phase I study to determine the safety and preliminary efficacy of autologous dendritic cells (DCs) loaded with multiple tumor neoantigen peptides administered as a cancer-treatment vaccine to treat adult postoperative patients with newly-diagnosed glioblastoma, in combination with the standard-of-care Temozolomide (TMZ) chemotherapy.

NCT ID: NCT03665545 Active, not recruiting - Clinical trials for Glioblastoma Multiforme

Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

IMA950-106
Start date: October 25, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status. Following diagnosis of relapsing glioblastoma by either brain CT scan or MRI, patients will be randomized in 2 arms: 1. Arm 1: IMA950 mixed with Poly-ICLC administered subcutaneously 2. Arm 2: Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly-ICLC administered subcutaneously The first phase of treatment will last 6 weeks, then surgery will be performed (done if clinically possible ad indicated). In case of available brain tissue, extensive analysis of the tumor immune response will be performed. Assessment of systemic immune response by PBMC immunomonitoring will be systematically done before and after surgery.

NCT ID: NCT02137759 Active, not recruiting - Clinical trials for Glioblastoma Multiforme of Brain

MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

Start date: May 7, 2014
Phase: Phase 2
Study type: Interventional

In the first phase of this study (Cohort 1), the investigators will determine the feasibility of adding MRSI to the evaluation of newly-diagnosed GBM patients treated with standard RT/TMZ and determine whether magnetic resonance spectroscopic imaging (MRSI) can predict for better outcomes in these patients. In the second phase of this study (Cohorts 2a and 2b), the investigators will find the maximum tolerated dose of belinostat for treating newly-diagnosed GBM patients with standard RT/TMZ and will determine whether MRSI can aid clinicians in the early determination of response to this new therapy.